# Biomedical Digest → ARP Pipeline Integration Plan
## 2026-05-01

---

## 1. Glyoxalase-I 타겟 추가

### 1.1 Glo-I 개요

```
Glyoxalase-I (Glo-I, GLOD1):
├── 위치: 세포질
├── 기질: Methylglyoxal (MGO)
├── 산물: S-lactoylglutathione
└── 기능: 당화 스트레스 해독

PATHWAY:
Glucose → Glycolysis → Methylglyoxal → Glo-I → D-lactate
                                     ↑
                               (당뇨, 노화, 산화스트레스)

노화에서의 역할:
├── MGO 축적 = 노화의 biomarker
├── Glo-I 활성 = 노화에 따라 감소
├── 단백질, DNA glycation 손상 유발
└── 억제 = 항노화 효과 가능
```

### 1.2 Glo-I 억제제 리뷰

```
KNOWN INHIBITORS:
├── S-alllyl cysteine (마늘)
├── Beer constituents (hops, barley)
├── Natural flavonoids
├── Synthetic analogs
└──力메틸글리옥살 자체도 inhibitor

CLINICAL RELEVANCE:
├── 당뇨병성 합병증
├── 신경퇴화 (알츠하이머)
├── 암 (항증식 효과)
├── 심혈관 질환
└── 노화 itself
```

### 1.3 ARP 파이프라인 통합

```
NEW TARGET ENTRY:

Glo-I (GLOD1):
├── Species: Human (HGNC: 4333)
├── Transcript: NM_006705.4
├── Protein: 184 aa, Zn-dependent
├── Location: Cytoplasm
├── PDB: 5JBG, 1QIP
├── Disease: Aging, Diabetes, Cancer
└── Priority: MEDIUM
```

---

## 2. Agentic Framework 통합

### 2.1 Nature Medicine 프레임워크 핵심

```
AGENTIC PIPELINE (Cancer Pathology):

┌──────────────────────────────────────────────────────────┐
│                    DATA LAYER                            │
│  ├──omics data (genomics, transcriptomics, proteomics)  │
│  ├──imaging data (pathology slides)                      │
│  ├──clinical records (EHR)                               │
│  └──literature (PubMed, bioRxiv)                        │
└──────────────────────────────────────────────────────────┘
                            │
                            ▼
┌──────────────────────────────────────────────────────────┐
│                  AGENT ORCHESTRATOR                      │
│  ├──Hypothesis Generation Agent                          │
│  ├──Experiment Design Agent                              │
│  ├──Literature Mining Agent                              │
│  └──Validation Agent                                    │
└──────────────────────────────────────────────────────────┘
                            │
                            ▼
┌──────────────────────────────────────────────────────────┐
│                   OUTPUT LAYER                           │
│  ├──Prioritized hypotheses                               │
│  ├──Experimental protocols                              │
│  ├──Target candidates ranked                            │
│  └──Publication-ready findings                          │
└──────────────────────────────────────────────────────────┘
```

### 2.2 ARP v24에 적용

```
현재 ARP 아키텍처:
┌─────────────┐
│ Director    │ ← 목표 할당, 작업 분배
├─────────────┤
│ Router      │ ← 작업 라우팅
├─────────────┤
│ Researcher  │ ← 문헌 수집
├─────────────┤
│ Analyst     │ ← 데이터 분석
├─────────────┤
│ Critic      │ ← 검증, 피드백
└─────────────┘

추가할 Agent:
┌─────────────┐
│ Hypothesis  │ ← 자동 가설 생성 (NEW)
│ Agent       │
├─────────────┤
│ Experiment  │ ← 실험 설계 최적화 (NEW)
│ Design      │
├─────────────┤
│ Self-Healing│ ← 자기 복구/검증 (기존 Peter Pang harness)
│ Harness     │
└─────────────┘
```

### 2.3 통합 구현

```
STEP 1: Hypothesis Agent 추가
├── 입력:疾病 데이터, 기존 문헌, 트렌드
├── 처리: LLM으로 가설 생성
├── 출력: 검증 가능한 가설 리스트
└── 도구: PubMed API, multi-agent reasoning

STEP 2: Experiment Design Agent
├── 입력:가설, 사용 가능한 자원
├── 처리: 최적 실험 설계 생성
├── 출력: protocol, readouts, statistical plan
└── 도구: EvanFlow TDD templates

STEP 3: Self-Healing Harness 통합
├── 입력:실행 결과, 오류 로그
├── 처리:자기 진단, 복구策略
├── 출력:수정된 실행 계획
└── 도구: Peter Pang framework
```

---

## 3. Attention Mechanism 적용

### 3.1 현재 상황

```
현재 ARP: 구조 기반 가상 스크리닝
├── 2D fingerprints
├── 3D docking (AutoDock, GOLD)
├── Physicochemical filters
└── Binding affinity prediction (IC50, Kd)

NOT IMPLEMENTED:
└── Attention-based binding prediction
```

### 3.2 적용 계획

```
ATTENTION-BASED DRUG DISCOVERY:

┌─────────────────────────────────────────┐
│           INPUT: Drug-Target Pair        │
└─────────────────────────────────────────┘
                      │
                      ▼
┌─────────────────────────────────────────┐
│      ATTENTION LAYER (Transformer)       │
│  ├── Drug structure (SMILES/Graph)      │
│  ├── Target binding site (PDB)          │
│  └── Interaction attention weights        │
└─────────────────────────────────────────┘
                      │
                      ▼
┌─────────────────────────────────────────┐
│           OUTPUT: Binding Score          │
│  ├── Affinity prediction                │
│  ├── Key residues identified            │
│  └── Interpretability (attention map)    │
└─────────────────────────────────────────┘

IMPLEMENTATION:
├── Tool: DeepDock, EquiBind, TankBind
├── Alternative: Ollama with Llama3 for reasoning
└── Integration: 기존 docking pipeline과 hybrid
```

---

## 4. Multimodal Aging 통합

### 4.1 Asynchronous Aging 모델

```
Nature Aging (2026):
└── Female reproductive organs age asynchronously

IMPLICATIONS:
├── Different organs have different aging rates
├── Organ-specific interventions may be needed
├── Biomarkers must be tissue-specific
└── Systems biology approach required

OUR GUT AGING PROJECT:
├── Gut = relatively fast aging organ
├── mTOR hyperactivation in gut
├── Citrulline supplementation
└── Connect to: Liver, pancreas, brain (gut-brain axis)
```

### 4.2 통합 모델

```
MULTI-ORGAN AGING:

Brain ──────────── Slow aging (neurons, post-mitotic)
     │
     │ (gut-brain axis)
     │
Gut ───────────── Fast aging (high turnover, microbiome)
     │
     │ (metabolic coupling)
     │
Liver ─────────── Moderate aging (metabolic hub)
     │
     │ (endocrine signaling)
     │
Heart ─────────── Slow aging (cardiomyocytes)
     │
     │ (systemic inflammation)
     │
Kidney ────────── Moderate aging (filtration burden)
     │
     │ (immune regulation)
     │
Lung ─────────── Moderate aging (environmental exposure)
```

### 4.3 Biomarker Panel

```
TISSUE-SPECIFIC AGING MARKERS:

Brain:     NfL, tau, amyloid-beta
Gut:       Citrulline, zonulin, LPS
Liver:     ALT, AST, albumin
Heart:     NT-proBNP, troponin
Kidney:    Creatinine, eGFR
Lung:      KL-6, SP-D

SYSTEMIC:
├── IL-6, TNF-α (inflammation)
├── CRP (acute phase)
├── Glo-I activity (methylglyoxal stress)
└── mTOR activity (S6K1 phosphorylation)
```

---

## 5. 통합 실행 계획

```
Q2 2026 (Current Quarter):

WEEK 1-2: Glyoxalase-I 타겟 추가
├── Literature search: Glo-I inhibitors
├── Target dossier creation
├── Virtual screening setup
└── Pilot: Natural product library

WEEK 3-4: Agentic Framework PoC
├── Hypothesis Agent prototype
├── Integration with existing pipeline
├── Test on gut aging project
└── Evaluation metrics defined

WEEK 5-6: Attention Mechanism
├── Install DeepDock/EquiBind
├── Test on DGAT1/SLC7A11 targets
├── Benchmark vs current docking
└── Documentation

WEEK 7-8: Multimodal Aging Integration
├── Gut aging data collection
├── Multi-organ biomarker panel
├── Asynchronous aging model
└── Connect to citrulline study

WEEK 9-10: Validation & Optimization
├── Self-healing harness full integration
├── Pipeline stress testing
├── Performance metrics
└── Documentation & training
```

---

## 6. 기술 스택

```
CURRENT STACK:
├── Language: Python 3.12
├── LLM: Ollama (qwen3:14b, glm-4.7)
├── Search: PubMed API, Brave Search
├── Docking: AutoDock Vina, RDKit
└── Pipeline: Custom orchestrator

ADDITIONS:
├── Agentic: LangChain/LangGraph (hypothesis generation)
├── Attention: DeepDock or EquiBind
├── Multi-omics: ScanPy (single-cell integration)
└── Self-healing: Peter Pang harness framework
```

---

## 7. Success Metrics

```
TARGET METRICS:

Scientific:
├── New targets identified: +3 (Glo-I, additional)
├── Hypothesis generation: <1 hour (vs 1 week manual)
├── Virtual screening accuracy: >70% (AUC)
└── Pipeline coverage: 5+ disease areas

Technical:
├── Agent collaboration success rate: >80%
├── Self-healing recovery rate: >90%
├── Attention model inference: <10 sec
└── End-to-end pipeline time: <24 hours

Business:
├── Target-to-candidate time: reduced 50%
├── Literature coverage: 100% (automated)
└── Repurposing success rate: >30%
```

---

## 8. Risks & Mitigations

```
RISK 1: Agent coordination complexity
├── Mitigation: Incremental integration, clear protocols
└── Fallback: Manual oversight during transition

RISK 2: Attention model accuracy
├── Mitigation: Ensemble with existing docking
└── Fallback: Use proven methods for critical decisions

RISK 3: Glyoxalase-I validation
├── Mitigation: Strong literature support
└── Fallback: Focus on established targets first

RISK 4: Multi-organ data integration
├── Mitigation: Phased approach, tissue-by-tissue
└── Fallback: Single-organ focus if complexity too high
```

---

*Document: arp-v24/BIOMED_DIGEST_PIPELINE_INTEGRATION_2026.md*  
*Created: 2026-05-01*